Bioequivalence and drug product assessment, in vivo

Generic Drug Product Development: Solid Oral Dosage Forms

Volumn , Issue , 2014, Pages 227-255

  Conner, Dale P ^a   Davit, Barbara M ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85081150771     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (45)

1. Kefauver-Harris Amendments. Public Law (PL) 87-781, 87th Congress, Oct. 10, 1962.
2. Drug Efficacy Study: A Report to the Commissioner of Food and Drugs, National Academy of Sciences, National Research Council, Washington, DC, 1969.
3. 34 Fed Regist 2673, Feb. 27, 1969.
4. 35 Fed Regist 6574, Apr. 24, 1970.
5. 35 Fed Regist 11273, Jul. 14, 1970.
6. Glazko AJ, Kinkel AW, Alegnani WC, Holmes EL. An evaluation of the absorption characteristics of different chloramphenicol preparations in normal human subjects. Clin Pharmacol Ther 1968; 9:472-483.
7. Barr WH, Gerbracht LM, Letchen K, Plaut M, Strahl N. Assessment of the biologic availability of tetracycline products in man. Clin Pharmacol Ther 1972; 13:97-108.
8. Chiou WL. Determination of physiological availability of commercial phenylbutazone preparations. Clin Pharmacol Ther1972; 12:296-299.
9. Blair DC, Barnes RW, Wildner EL, Murray WJ. Biologic availability of oxytetra-cycline HCl capsules: a comparison of all manufacturing sources supplying the United States market. JAMA 1971; 215:251-254.
10. Lindenbaum J. et al. Variations in biological availability of digoxin from four preparations. N Eng J Med 1971; 285:1344.
11. Office of Technology Assessment. Drug Bioequivalence. A Report of the Office of Technology Assessment Drug Bioequivalence Study Panel, US Government Printing Office, Washington, DC, 1974.
12. Office of Technology Assessment. Scientific commentary: Drug bioequivalence. J Pharmacokinet Biopharm 1974; 2:433-466.
13. 42 Fed Regist 1648, Jan. 7, 1977.
14. 57 Fed Regist 17950, Apr. 28, 1992.
15. Drug Price Competition and Patent Term Restoration Act of 1984, Public Law 98-417, 98 Stat 1585-1605, Sept. 24, 1984.
16. 57 Fed Regist 17998, Apr. 28, 1992.
17. Food and Drug Administration, Center for Drug Evaluation and Research. Approved Drug Products with Therapeutic Equivalence Evaluations. 24th ed. Superintendent of Documents. Washington, DC: US Government Printing Office, 2004.
18. Dighe SV, Adams WP. Bioequivalence: a United States regulatory perspective. In: Welling PG, Tse FLS, Dighe SV, eds. Pharmaceutical Bioequivalence. New York: Marcel Dekker, Inc, 1991:347-380.
19. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15:657-680.
20. Gibaldi M, Perrier D. Absorption kinetics and bioavailability. In: Pharmacoki-netics. 2nd New York: Marcel Dekker, 1982:145-198.
21. Hauck WW, Anderson S. A new statistical procedure for testing equivalence in two-group comparative bioavailability studies. J Pharmacokinet Biopharm 1984; 12:83-91.
22. US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. Jan. 2001.
23. US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations. Mar. 19, 2003.
24. Freedom of Information Staff, Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, MD. Summary Basis of Approval.
25. US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Draft Guidance for Industry: Food-Effect Bioavailability and Bioequivalence Studies. Dec. 2002.
26. US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Draft Guidance for Industry: Clozapine Tablets In Vivo Bioequivalence and In Vitro Dissolution Testing. Feb. 29, 2003.
27. 57 Fed Regist 29354, Jul. 1, 1992.
28. US Dept of Health and Human Services, Food and Drug Administration, Cen-ter for Drug Evaluation and Research. Draft Guidance for Industry: Potassium Chloride (slow-release tablets and capsules) In Vivo Bioequivalence and In Vitro Dissolution Testing. Aug. 6, 2002.
29. US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Topical Dermatologic Corticosteroids: In Vivo Bioequivalence. Mar. 6, 1998.
30. US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Interim Guidance for Industry: Cholestyramine Powder In Vitro Bioequivalence. Jul. 15, 1993.
31. Swenson CN, Fundak G. Observational cohort study of switching warfarin sodium products in a managed care organization. Amer J Health Syst Pharm 2000; 57:452-455.
32. US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. Aug. 31, 2000.
33. Nightingale S. From the Food and Drug Administration. JAMA 1998; 279:645.
34. Advisors and Consultants Staff, Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, MD. Meeting of the Advisory Committee for Pharmaceutical Science. Nov. 16, 2000.
35. 68 Fed Regist 61640, October 29, 2003.
36. Health Canada. Therapeutic Products Directorate Guideline: Preparation of Drug Submissions: Comparative Bioavailability Studies. 1997.
37. Canadian Reference product: Policy Issue from the Drugs Directorate. Use of a non-Canadian Reference Product, Section C.08.002.1 (c) of then Food and Drug Regulations, December 5, 1995.
38. Health Canada. Therapeutic Products Directorate Guideline: Conduct and Analysis of Bioavailability and Bioequivalence Studies-Part A: Oral Dosage Formulations Used for Systemic Effects. 1992.
39. Health Canada. Therapeutic Products Directorate Guideline: Conduct and Analysis of Bioavailability and Bioequivalence Studies-Part B: Oral Modified Release Formulations. 1996.
40. Health Canada. Report C. Expert Advisory Committee on Bioavailability, Report on Bioavailability of Oral Dosage Formulations, not in Modified Release Form, of Drugs Used for Systemic Effects, Having Complicated or Variable Pharmacokinetics. 1992.
41. Health Canada. Therapeutic Products Directorate Draft Guideline: Standards for Comparative Bioavailability Studies Involving Drugs with a Narrow Therapeutic Range. 1997.
42. Health Canada. Therapeutic Products Directorate Draft Guideline: Bioequivalence Requirements (Draft): Drugs Exhibiting Non-Linear Pharmacokinetics. 1997.
43. National Institute of Health Sciences, Japan. Guideline for Bioequivalence Studies of Generic Products. 1997.
44. http://www.eurunion.org/states/home.htm.
45. The European Agency for the Evaluation of Medicinal Products. Note for Guidance on the Investigation of Bioavailability and Bioequivalence. Jul. 26, 2001.